TSXV:NRX - Post Discussion
Post by
cmarketinsights on Jan 03, 2025 5:34pm
A New Frontier in Regenerative Medicine
A New Frontier in Regenerative Medicine NurExone Biologic Inc. (TSXV: NRX) , an Israeli biotech company, is developing a novel exosome-based drug delivery platform aimed at treating central nervous system injuries, including spinal cord and optic nerve injuries. Their lead therapy, ExoPTEN, has already received orphan drug designation from both the FDA and EMA, highlighting its potential significance in addressing unmet medical needs. With preclinical studies completed and plans for phase one trials by the end of 2025, the company is positioning itself in an emerging industry that currently has no FDA-approved exosome therapeutics. Could this innovative approach reshape the treatment landscape for conditions like acute spinal cord injury? Read the full report here: https://www.researchfrc.com/content/reports/post/188/a-potential-breakthrough-in-spinal-cord-and-optic-nerve-injury-treatment
Be the first to comment on this post